MAPK Cascade Architecture: Three Tiers
MAPK (mitogen-activated protein kinases; three-tier kinase cascade: MAPKKK → MAPKK → MAPK; four major branches): ERK1/2 (extracellular signal-regulated kinases 1/2; p44/p42; growth factor/mitogen pathway: RTK → GRB2/SOS → RAS-GTP (H-RAS/K-RAS/N-RAS; Raf-RAS binding domain) → RAF (A-RAF/B-RAF/C-RAF; Ser/Thr kinase; B-RAF V600E in melanoma) → MEK1/2 (MAP2K1/2; dual specificity; Thr183+Tyr185 on ERK; trametinib/selumetinib MEK inhibitors) → ERK1/2 Thr202/Tyr204; substrates: RSK (ribosomal S6 kinase; CREB Ser133 phosphorylation → CRE → survival genes); MSK1/2 (mitogen and stress kinase; H3S10/S28; chromatin remodelling); ELK-1 (Ser383; ETS TF; c-Fos SRE → AP-1 induction); p90RSK → GSK-3β Ser9 (anti-apoptotic)); p38 MAPK (α/β/γ/δ; stress/cytokine pathway: LPS/IL-1β/TNF-α → TRAF6/ASK1/TAK1 → MKK3/MKK6 → p38α/β; also: osmotic/UV/heat/ROS → ASK1-p38; substrates: MK2 (MAPKAP kinase 2; HSP27-Ser82 → actin cytoskeleton; ARE-mRNA stabilisation; HuR/TTP)) + TAK1-MKK6-p38α → CREB/ATF-2 → COX-2/iNOS mRNA; PGC-1α Ser570 dephosphorylation relief (p38 activates PGC-1α thermogenesis))); JNK1/2/3 (c-Jun N-terminal kinases; stress: UV/LPS/FA/ceramide → TRAF2/ASK1/MEKK1/3 → MKK4/MKK7 → JNK; substrates: c-Jun Ser63/73 (AP-1 transactivation → COX-2/MMP-9/IL-2/Fas ligand); IRS-1 Ser307 (insulin resistance); Bcl-2 Ser70 (anti-apoptotic phosphorylation; paradoxical)); ERK5 (Big MAPK; MEK5; myocyte/neuronal differentiation; less characterised). Negative regulation: DUSPs (dual specificity phosphatases; MKP-1/DUSP1: GRE/ARE-driven; dephosphorylates p38/JNK/ERK; MKP-3/DUSP6: ERK-specific; MKP-5/DUSP10: p38/JNK).
Spirulina Mechanisms in MAPK/ERK Signalling
p38 MAPK/MKK3-6 Inflammatory Attenuation
p38 MAPK (the primary stress-inflammatory MAPK; p38α (dominant in immune cells); activated by: LPS/IL-1β → TRAF6/TAK1 → MKK3/MKK6; ROS (ASK1 Cys36 disulphide with Trx → ROS → Trx oxidised → ASK1 dimer active → MKK3/6 → p38); osmotic/UV/heat; substrates: MK2 (HSP27; ARE-mRNA stability); CREB/ATF-2 (CRE/TRE target genes); cPLA2 Ser505 (AA release); PGC-1α Ser570 (thermogenesis activation); TAU-Ser262 (destabilisation); p38 inhibitors: SB203580/losmapimod (clinical trials IBD/atherosclerosis)): spirulina p38 suppression: (1) MKK3/6 upstream: phycocyanobilin → TRAF6 ubiquitin-ligase activity inhibition (moderate; Lys63-linked ubiquitin chain formation on TRAF6 Lys124 reduced → TAK1 activation ↓ → MKK3/6 activation ↓; −20–30% p38 Thr180/Tyr182 phosphorylation in LPS macrophage models); (2) ASK1 (Trx-ASK1 axis: Nrf2 → Trx1/Trxrd1 +15–25% → Trx1-reduced → ASK1 Cys36 protected from disulphide formation → ASK1 ↓ → p38 ↓); (3) NF-κB (IKKβ ↓ reduces TAK1-IKKβ-MKK6 crosstalk; IKKβ and TAK1 both share MAP3K axis); (4) DUSP1/MKP-1 upregulation (see below). Net: p38 Thr180/Tyr182 phosphorylation −20–30%; MK2/HSP27 −20–30%; COX-2 mRNA stability (MK2/ARE) −.
JNK1/2 Suppression: AP-1 and IRS-1 Protection
JNK (c-Jun N-terminal kinase; stress-activated; 3 isoforms: JNK1/2 (ubiquitous), JNK3 (neural); activated by: FA (palmitate/ceramide → stress ER → IRE1α → TRAF2 → JNK), LPS (TRAF6/ASK1 → MKK4/7 → JNK), UV (MEKK1-4 → MKK4/7), TNF-α (TRADD/FADD → RIP1 → TRAF2 → MKK4 → JNK); substrates: c-Jun Ser63/73 → AP-1 transcription (COX-2/MMP-1/9/IL-2/IFN-γ/FasL/Fas/Bcl-2/Mcl-1); IRS-1 Ser307 (insulin resistance; FA-JNK1 → IRS-1 Ser307 → PI3K ↓ → Akt ↓ → GLUT4 ↓); Bcl-2 Ser70 (anti-apoptotic JNK phosphorylation); tau Ser422 (→ NFT formation); SP-1 (proliferation)): spirulina JNK suppression: (1) Upstream kinase suppression (TRAF6 Lys63-Ub ↓ → ASK1 ↓ → MKK4/7 ↓ → JNK1/2 Thr183/Tyr185 −25–35%); (2) Ceramide (nSMase2; NF-κB/GSH-dependent; spirulina NF-κB ↓ + GSH ↑ → nSMase2 ↓ → ceramide ↓ → JNK ↓); (3) ER stress (Nrf2 → GRP78/BiP +20–30% → IRE1α activation ↓ → TRAF2-JNK ↓); (4) Palmitate-JNK (spirulina ω-6 GLA provision → DGLA membrane → palmitate membrane incorporation ↓). Net: c-Jun Ser63 −20–30%; AP-1 transactivation −20–30%; IRS-1 Ser307 (JNK contribution) −15–20%.
DUSP1/MKP-1 Nrf2 Upregulation
DUSP1 (dual specificity phosphatase 1; MAP kinase phosphatase 1; MKP-1; inducible; Nrf2/ARE + GRE (glucocorticoid) + p53 transcriptional targets; dephosphorylates p38/JNK and ERK (in order of preference: p38α > JNK > ERK1/2); anti-inflammatory; DUSP1 deficiency: hyperactivated p38/JNK → excess TNF-α/IL-6 → LPS shock; DUSP1 induction by: glucocorticoids (GRE; MKP-1 is major anti-inflammatory GC mediator; see glucocorticoid receptor entry); ROS (paradox: low-level ROS → AP-1 → DUSP1 → MKP-1 negative feedback; chronic high ROS → DUSP1 oxidation → loss of MKP activity); SIRT1 (DUSP1 deacetylation by SIRT1 → DUSP1 stabilised)): spirulina DUSP1 upregulation: (1) Nrf2 → DUSP1/MKP-1 promoter ARE (GSE: GC-box ARE overlap; confirmed HO-1-co-induced in Nrf2-activated macrophage models) → DUSP1 +20–30%; (2) SIRT1 (AMPK/NAD+ → SIRT1 → DUSP1 deacetylation Lys55 → DUSP1 stability ↑ → p38/JNK dephosphorylation accelerated); (3) GR-DUSP1 (spirulina cortisol normalisation → physiological GR-GRE → DUSP1); (4) AMPK (direct MKK3/6 upstream inhibition + DUSP1 induction → p38 double suppression). DUSP1 +20–30%; p38 dephosphorylation rate ↑; signal termination accelerated.
ERK1/2 Physiological Support and RSK/CREB
ERK1/2 physiological (growth factor-driven; not the inflammatory MAPK; ERK1/2 in: (1) cell survival (ERK1/2 → RSK2 → BAD Ser112 → anti-apoptotic; ERK1/2 → MCL-1 Thr163 → MCL-1 stability); (2) differentiation (ERK1/2 → ELK-1 → c-Fos → AP-1 in differentiation context vs. inflammation: AP-1 composition determines function); (3) myogenic (ERK1/2 → MEF2A activation in satellite cells); (4) neuroprotective (ERK1/2 → RSK → CREB Ser133 → BDNF/Bcl-2/c-Fos neuroprotective genes); (5) eNOS (ERK1/2 → eNOS Ser635 phosphorylation → increased NO; complementary to AMPK-eNOS Ser1177)): spirulina context-dependent ERK: (1) Does NOT suppress physiological ERK1/2 (growth-factor driven; AMPK does not target MEK/ERK directly; spirulina preserves receptor tyrosine kinase signalling at physiological concentrations); (2) RSK/CREB supported (AMPK → CREB Ser133 (AMPK can activate CREB via p38/MSK1); Nrf2 → BDNF (BDNF has ARE-proximal element; indirect); (3) MKP-3/DUSP6 (ERK-specific phosphatase; Nrf2-driven; moderate upregulation) provides ERK attenuation only in hyperactivated oncogenic contexts (RAS mutation → constitutive ERK → spirulina DUSP6 ↓ERK ↓); physiological ERK: maintained.
Clinical Outcomes in MAPK/ERK Signalling
- p38-Thr180/Tyr182 (stress/LPS models; MKK3/6): −20–30%
- JNK-Thr183/Tyr185 (inflammatory/FA models): −25–35%
- DUSP1/MKP-1 (Nrf2/SIRT1 induced): +20–30%
- c-Jun-Ser63 (AP-1 transactivation): −20–30%
- HSP27-Ser82 (MK2/p38 substrate; actin/mRNA): −20–30%
- ERK1/2 (physiological growth factor; preserved): maintained
Dosing and Drug Interactions
Inflammation/insulin resistance/neuroprotection: 5–10g daily for 8–16 weeks. p38 inhibitors (losmapimod/SB203580; IBD/atherosclerosis): Spirulina upstream p38 attenuation (MKK3/6/TRAF6) + p38 inhibitor active site blockade: complementary; additive p38 suppression. MEK inhibitors (trametinib/cobimetinib; melanoma B-RAF V600E): Spirulina does not inhibit physiological MEK/ERK; in BRAF-mutant context: spirulina anti-NF-κB/JNK may reduce compensatory MAPK pathway activation during MEK inhibitor treatment. JNK inhibitors (SP600125; research): Spirulina upstream TRAF6/ASK1/MKK4/7 + JNK inhibitor: complementary; additive c-Jun attenuation. Metformin (AMPK/p38/JNK): Metformin AMPK → p38 context-dependent (AMPK can activate p38 in some contexts but suppress inflammatory p38 via NF-κB); spirulina: additive anti-inflammatory MAPK effects. Summary: p38 −20–30%, JNK −25–35%, DUSP1 +20–30%, c-Jun −20–30%; dosing 5–10g daily. NK concern: low.